Agreement-to-acquire-NBE-Therapeutics

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates  Acquisition will add another key dimension to Boehringer Ingelheim ’s focus on patients with difficult-to-treat solid tumors NBE-Therapeutics ’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform NBE-Therapeutics ’ will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network  
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news